News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,664 Results
Type
Article (46150)
Company Profile (334)
Press Release (661180)
Section
Business (208952)
Career Advice (2171)
Deals (35959)
Drug Delivery (103)
Drug Development (82106)
Employer Resources (187)
FDA (16266)
Job Trends (15197)
News (351988)
Policy (33150)
Tag
Academia (2719)
Alliances (50641)
Alzheimer's disease (1268)
Approvals (16191)
Artificial intelligence (144)
Bankruptcy (357)
Best Places to Work (11724)
Biotechnology (230)
Breast cancer (123)
Cancer (1105)
Cardiovascular disease (100)
Career advice (1819)
Cell therapy (248)
Clinical research (64956)
Collaboration (401)
Compensation (198)
COVID-19 (2610)
C-suite (99)
Data (1125)
Diabetes (154)
Diagnostics (6290)
Earnings (85667)
Employer resources (161)
Events (112952)
Executive appointments (313)
FDA (16804)
Funding (358)
Gene therapy (189)
GLP-1 (622)
Government (4476)
Healthcare (19046)
Infectious disease (2698)
Inflammatory bowel disease (111)
Interviews (341)
IPO (16505)
Job creations (3835)
Job search strategy (1565)
Layoffs (433)
Legal (8012)
Lung cancer (177)
Manufacturing (185)
Medical device (13328)
Medtech (13333)
Mergers & acquisitions (19526)
Metabolic disorders (424)
Neuroscience (1557)
NextGen Class of 2024 (6702)
Non-profit (4633)
Northern California (1488)
Obesity (249)
Opinion (197)
Patents (105)
People (58237)
Phase I (20175)
Phase II (28601)
Phase III (21328)
Pipeline (457)
Postmarket research (2633)
Preclinical (8814)
Radiopharmaceuticals (242)
Rare diseases (223)
Real estate (6209)
Regulatory (21957)
Research institute (2463)
Resumes & cover letters (374)
Southern California (1308)
Startups (3764)
United States (13695)
Vaccines (575)
Weight loss (186)
Date
Today (132)
Last 7 days (857)
Last 30 days (3831)
Last 365 days (36388)
2024 (33355)
2023 (40858)
2022 (51924)
2021 (56501)
2020 (54904)
2019 (47648)
2018 (35937)
2017 (33086)
2016 (32665)
2015 (38767)
2014 (32375)
2013 (27536)
2012 (29798)
2011 (30536)
2010 (29032)
Location
Africa (788)
Arizona (201)
Asia (38792)
Australia (6371)
California (3359)
Canada (1288)
China (251)
Colorado (149)
Connecticut (153)
Europe (84124)
Florida (459)
Georgia (124)
Illinois (356)
Indiana (203)
Kansas (98)
Maryland (589)
Massachusetts (2645)
Michigan (170)
Minnesota (288)
New Jersey (967)
New York (969)
North Carolina (734)
Northern California (1488)
Ohio (140)
Pennsylvania (849)
South America (1166)
Southern California (1308)
Texas (468)
Utah (92)
Washington State (364)
707,664 Results for "kodiak sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kodiak Sciences to Participate in Upcoming Investor Conferences
November 11, 2024
·
3 min read
Biotech Bay
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.
May 29, 2024
·
4 min read
Press Releases
Kodiak Sciences to Present at Innovate Retina 2024
October 15, 2024
·
3 min read
Business
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.
May 15, 2024
·
16 min read
Biotech Bay
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak’s Antibody Biopolymer Conjugate (ABC) Platform
Kodiak Sciences Inc. announced that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington.
May 2, 2024
·
14 min read
Business
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Kodiak Sciences Inc., reported business highlights and financial results for the quarter and year ended December 31, 2023.
March 28, 2024
·
24 min read
Drug Development
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.
May 13, 2024
·
9 min read
Press Releases
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
September 23, 2024
·
1 min read
Business
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
September 17, 2024
·
10 min read
Business
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024.
March 26, 2024
·
5 min read
1 of 70,767
Next
